MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Gross Profit 2011-2026 | QTNT
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 23.3 M | 14.9 M | 11.9 M | 14.3 M | 11.4 M | 8.86 M | 8.64 M | 11.3 M | 7.2 M | 5.47 M | 4.41 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.3 M | 4.41 M | 11.1 M |
Quarterly Gross Profit Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.05 M | -3.52 M | -9.57 M | - | 2.24 M | 11.1 M | 8.9 M | 3.8 M | 3.78 M | 3.78 M | 11.6 M | 3.51 M | 3.41 M | 3.41 M | 3.88 M | 3.61 M | 2.54 M | 2.54 M | 1.7 M | - | 3.53 M | 3.12 M | 3.99 M | - | 2.24 M | 8.25 M | 6.01 M | - | 2.13 M | 6.38 M | 4.25 M | - | 1.86 M | 7.14 M | 5.29 M | - | 1.97 M | 8.83 M | 6.86 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.6 M | -9.57 M | 4.08 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
2.84 B | $ 111.16 | -2.04 % | $ 33.8 B |  USA |
 |
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
2.26 B | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Sotera Health Company
SHC
|
646 M | $ 13.26 | -2.07 % | $ 3.77 B | USA |
|
Biodesix
BDSX
|
18.5 M | $ 14.28 | -2.19 % | $ 1.85 B | USA |
 |
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M |  Britain |
 |
BioNano Genomics
BNGO
|
2.77 M | $ 1.14 | -1.3 % | $ 6.21 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
364 M | $ 16.25 | -12.16 % | $ 175 M |  China |
 |
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | USA |
 |
Co-Diagnostics
CODX
|
2.63 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
53 M | $ 24.03 | -2.71 % | $ 667 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
958 M | $ 158.22 | -4.18 % | $ 7.84 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 196.67 | -0.75 % | $ 21.8 B | USA |
 |
Organovo Holdings
ONVO
|
1.87 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
366 K | - | -16.95 % | $ 1.54 M | USA |
 |
DarioHealth Corp.
DRIO
|
12.7 M | $ 8.45 | - | $ 33.7 M |  Israel |
 |
DexCom
DXCM
|
2.8 B | $ 62.38 | -5.61 % | $ 24.3 B | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 15.72 | -4.06 % | $ 475 M | USA |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
144 M | $ 84.78 | -3.77 % | $ 10.6 B | USA |
 |
PerkinElmer
PKI
|
523 M | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
98.7 M | - | - | $ 21.2 M | USA |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 102.7 | -0.37 % | $ 8.47 B |  Irlanda |
 |
Illumina
ILMN
|
2.86 B | $ 118.42 | -4.81 % | $ 18.8 B | USA |
 |
Interpace Biosciences
IDXG
|
29.9 M | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
IQVIA Holdings
IQV
|
3.79 B | $ 165.13 | -2.52 % | $ 28.4 B | USA |
 |
Lantheus Holdings
LNTH
|
942 M | $ 74.66 | -2.23 % | $ 5.04 B | USA |
 |
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
967 M | - | - | $ 10.6 B |  Niderland |
 |
Medpace Holdings
MEDP
|
246 M | $ 455.39 | -2.4 % | $ 13.1 B | USA |
 |
Mettler-Toledo International
MTD
|
2.39 B | $ 1 240.08 | -2.36 % | $ 25.6 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
577 M | $ 4.43 | -4.22 % | $ 410 M | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.7 | 2.4 % | $ 2.52 M | USA |
 |
NeoGenomics
NEO
|
314 M | $ 7.55 | -2.77 % | $ 967 M | USA |
 |
Neogen Corporation
NEOG
|
421 M | $ 8.85 | -3.33 % | $ 1.92 B | USA |
 |
National Research Corporation
NRC
|
81.5 M | $ 17.23 | -0.78 % | $ 386 M | USA |
 |
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | USA |